High-Grade Astrocytoma with Piloid Features: A Dual Institutional Review of Imaging Findings of a Novel Entity

References

1. 1.↵
   2. Osborn AG,
   3. Louis DN,
   4. Poussaint TY, et al

   . The 2021 World Health Organization Classification of Tumors of the Central Nervous System: what neuroradiologists need to know. AJNR Am J Neuroradiol 2022;43:928–37 doi:10.3174/ajnr.A7462 pmid:35710121

   Abstract/FREE Full Text
2. 2.↵
   2. Rigsby RK,
   3. Brahmbhatt P,
   4. Desai AB, et al

   . Newly recognized CNS tumors in the 2021 World Health Organization Classification: imaging overview with histopathologic and genetic correlation. AJNR Am J Neuroradiol 2023;44:367–80 doi:10.3174/ajnr.A7827 pmid:36997287

   Abstract/FREE Full Text
3. 3.↵
   2. Capper D,
   3. Jones DTW,
   4. Sill M, et al

   . DNA methylation-based classification of central nervous system tumours. Nature 2018;555:469–74 doi:10.1038/nature26000 pmid:29539639

   CrossRefPubMed
4. 4.↵
   2. Reinhardt A,
   3. Stichel D,
   4. Schrimpf D, et al

   . Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol 2018;136:273–91 doi:10.1007/s00401-018-1837-8 pmid:29564591

   CrossRefPubMed
5. 5.↵
   2. Louis DN,
   3. Perry A,
   4. Wesseling P, et al

   . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23:1231–51 doi:10.1093/neuonc/noab106 pmid:34185076

   CrossRefPubMed
6. 6.↵
   2. Cimino PJ,
   3. Ketchum C,
   4. Turakulov R, et al

   . Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1. Acta Neuropathol 2023;145:71–82 doi:10.1007/s00401-022-02513-5 pmid:36271929

   CrossRefPubMed
7. 7.↵
   2. Bender K,
   3. Perez E,
   4. Chirica M, et al

   . High-grade astrocytoma with piloid features (HGAP): the Charité experience with a new central nervous system tumor entity. J Neurooncol 2021;153:109–20 doi:10.1007/s11060-021-03749-z pmid:33905054

   CrossRefPubMed
8. 8.↵
   2. Reinhardt A,
   3. Stichel D,
   4. Schrimpf D, et al

   . Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. Acta Neuropathol Commun 2019;7:163 doi:10.1186/s40478-019-0801-8 pmid:31661039

   CrossRefPubMed
9. 9.↵
   2. Kleinschmidt-DeMasters BK,
   3. Ormond DR

   . Leptomeningeal metastases and dural spread in adult high-grade astrocytomas. J Neuropathol Exp Neurol 2023;82:194–201 doi:10.1093/jnen/nlac126 pmid:36637258

   CrossRefPubMed
10. 10.↵
    2. Miguel Llordes G,
    3. Medina Pérez VM,
    4. Curto Simón B, et al

    . Epidemiology, diagnostic strategies, and therapeutic advances in diffuse midline glioma. J Clin Med 2023;12:5261 doi:10.3390/jcm12165261 pmid:37629304

    CrossRefPubMed
11. 11.↵
    2. Maruoka R,
    3. Takenouchi T,
    4. Torii C, et al

    . The use of next-generation sequencing in molecular diagnosis of neurofibromatosis type 1: a validation study. Genet Test Mol Biomarkers 2014;18:722–35 doi:10.1089/gtmb.2014.0109 pmid:25325900

    CrossRefPubMed
12. 12.↵
    2. Yamashita K,
    3. Hiwatashi A,
    4. Togao O, et al

    . MR imaging–based analysis of glioblastoma multiforme: estimation of IDH1 mutation status. AJNR Am J Neuroradiol 2016;37:58–65 doi:10.3174/ajnr.A4491 pmid:26405082

    Abstract/FREE Full Text
13. 13.↵
    2. Lucas CH,
    3. Sloan EA,
    4. Gupta R, et al

    . Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. Acta Neuropathol 2022;144:747–65 doi:10.1007/s00401-022-02478-5 pmid:35945463

    CrossRefPubMed
14. 14.↵
    2. Lobbous M,
    3. Bernstock JD,
    4. Coffee E, et al

    . An update on neurofibromatosis type 1-associated gliomas. Cancers (Basel) 2020;12:12 doi:10.3390/cancers12010114 pmid:31906320

    CrossRefPubMed
15. 15.↵
    2. Tao J,
    3. Sun D,
    4. Dong L, et al

    . Advancement in research and therapy of NF1 mutant malignant tumors. Cancer Cell Int 2020;20:492 doi:10.1186/s12935-020-01570-8 pmid:33061844

    CrossRefPubMed
16. 16.↵
    2. Romo CG,
    3. Piotrowski AF,
    4. Campian JL, et al

    . Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1. Neuro Oncol 2023;25:1474–86 doi:10.1093/neuonc/noad033 pmid:36840626

    CrossRefPubMed
17. 17.↵
    2. Russo C,
    3. Russo C,
    4. Cascone D, et al

    . Non-oncological neuroradiological manifestations in NF1 and their clinical implications. Cancers (Basel) 2021;13:1831 doi:10.3390/cancers13081831 pmid:33921292

    CrossRefPubMed
18. 18.↵
    2. Galbraith K,
    3. Snuderl M

    . DNA methylation as a diagnostic tool. Acta Neuropathol Commun 2022;10:71 doi:10.1186/s40478-022-01371-2 pmid:35527288

    CrossRefPubMed
19. 19.↵
    2. Haase S,
    3. Garcia-Fabiani MB,
    4. Carney S, et al

    . Mutant ATRX: uncovering a new therapeutic target for glioma. Expert Opin Ther Targets 2018;22:599–613 doi:10.1080/14728222.2018.1487953 pmid:29889582

    CrossRefPubMed
20. 20.↵
    2. Collins VP,
    3. Jones DT,
    4. Giannini C

    . Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol 2015;129:775–88 doi:10.1007/s00401-015-1410-7 pmid:25792358

    CrossRefPubMed
21. 21.↵
    2. Jones DT,
    3. Hutter B,
    4. Jäger N, et al

    ; International Cancer Genome Consortium PedBrain Tumor Project. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 2013;45:927–32 doi:10.1038/ng.2682 pmid:23817572

    CrossRefPubMed
22. 22.↵
    2. Marker DF,
    3. Agnihotri S,
    4. Amankulor N, et al

    . The dominant TP53 hotspot mutation in IDH-mutant astrocytoma, R273C, has distinctive pathologic features and sex-specific prognostic implications. Neurooncol Adv 2022;4:vdab182 doi:10.1093/noajnl/vdab182 pmid:35047821

    CrossRefPubMed
23. 23.↵
    2. Fontebasso AM,
    3. Schwartzentruber J,
    4. Khuong-Quang DA, et al

    . Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol 2013;125:659–69 doi:10.1007/s00401-013-1095-8 pmid:23417712

    CrossRefPubMed
24. 24.↵
    2. Nomura M,
    3. Mukasa A,
    4. Nagae G, et al

    . Distinct molecular profile of diffuse cerebellar gliomas. Acta Neuropathol 2017;134:941–56 doi:10.1007/s00401-017-1771-1 pmid:28852847

    CrossRefPubMed
25. 25.↵
    2. Theeler BJ,
    3. Ellezam B,
    4. Sadighi ZS, et al

    . Adult pilocytic astrocytomas: clinical features and molecular analysis. Neuro Oncol 2014;16:841–47 doi:10.1093/neuonc/not246 pmid:24470550

    CrossRefPubMed
26. 26.↵
    2. Chourmouzi D,
    3. Papadopoulou E,
    4. Konstantinidis M, et al

    . Manifestations of pilocytic astrocytoma: a pictorial review. Insights Imaging 2014;5:387–402 doi:10.1007/s13244-014-0328-2 pmid:24789122

    CrossRefPubMed
27. 27.↵
    2. Zhao JP,
    3. Liu XJ,
    4. Lin HZ, et al

    . MRI comparative study of diffuse midline glioma, H3 K27-altered and glioma in the midline without H3 K27-altered. BMC Neurol 2022;22:498 doi:10.1186/s12883-022-03026-0 pmid:36550486

    CrossRefPubMed
28. 28.↵
    2. Vallero SG,
    3. Bertero L,
    4. Morana G, et al

    . Pediatric diffuse midline glioma H3K27-altered: A complex clinical and biological landscape behind a neatly defined tumor type. Front Oncol 2022;12:1082062 doi:10.3389/fonc.2022.1082062 pmid:36727064

    CrossRefPubMed
29. 29.↵
    2. Aboian MS,
    3. Solomon DA,
    4. Felton E, et al

    . Imaging characteristics of pediatric diffuse midline gliomas with histone H3 K27M mutation. AJNR Am J Neuroradiol 2017;38:795–800 doi:10.3174/ajnr.A5076 pmid:28183840

    Abstract/FREE Full Text